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Background: Very little is known about pulmonary hypertension and right ventricular (RV) function after transcatheter aortic valve replacement 
(TAVR). The aim of this study is to assess changes in echo measures of pulmonary hypertension and RV function following TAVR, compared to surgical 
aorticvalve replacement (sAVR).
Methods: Forty-seven consecutive patients with symptomatic, severe aortic stenosis who underwent TAVR with the Edwards SAPIEN valve (Edwards 
Lifesciences, Inc., Irvine, California) and sAVR between August 2007 and June 2009. Transthoracic echocardiography was performed at baseline, 
discharge, 1 month, 6 months, 1 year and 2 years. Routine measurements included tricuspid regurgitation (TR) velocity, pulmonary vascular 
resistance (PVR) and RV functional indices of RV velocity time integral (VTI) and tissue Doppler S’ velocity.
results: Thirty one TAVR patients and 16 age, sex-matched sAVR patients were studied. Baseline echocardiographic data was not significantly 
different between the two groups except TAVR patients had a lower ejection fraction (52.15 ± 11.35 vs 59.3 ± 5.2 %, p=0.022). In the TAVR group, 
there was a significant reduction in TR peak velocity from baseline to follow-up (3.00 ± 0.46 vs 2.69 ± 0.57m/sec, p=0.045 at 2 yrs) and PVR (2.74 
± 0.95 vs 2.04± 0.65 WU, p=0.023 at 1 yr) with significant increase in RV VTI (13.08 ± 3.35 vs 15.32 ±4.29 cm, p=0.041at 1yr) and S’ velocity 
(11.72 ± 3.98 vs 16.94 ± 4.79 cm/s, p<0.001 at 6 months; 10.47 ± 4.44 vs 17.00 ± 6.96 cm/s, p=0.001 at 1 year). In the sAVR group, there was 
only a reduction in TR peak velocity (2.91± 0.62 vs 2.46± 0.52 m/s, p=0.025 at 1 month; 2.90 ± 0.50 vs 2.42± 0.54 m/s, p=0.049 at 6 months) 
with no significant change in PVR, RV VTI and S’ velocity. By 2 years, there was no significant between group differences in these parameters.
conclusions: Patients undergoing TAVR may have earlier improvement in pulmonary hypertension and RV function compared to sAVR. There was 
comparable improvement by 2-years follow-up.
